增强CT在新辅助化疗后卵巢癌残留病灶检测中的价值
回顾性观察队列研究纳入58例III/IV期卵巢癌新辅助化疗后行间歇性减瘤术患者,评估增强CT预测残留病灶的诊断性能。患者分析敏感度92.16%、特异度57.14%、阴性预测值50.00%、准确率87.93%;病灶分析敏感度63.01%、特异度73.47%、阴性预测值50.00%、准确率66.51%。假阴性结果与病灶大小相关(p < 0.001),在膈下间隙、肠浆膜和肠系膜检出腹膜癌病的诊断性能低(p < 0.001)。
要点
- 患者分析阴性预测值仅50.00%,CT判断无残留病灶的可靠性有限。
- 病灶分析敏感度63.01%,非可测量病灶易被漏诊。
- 膈下间隙、肠浆膜和肠系膜腹膜癌病检出性能低(p < 0.001)。
核心结论
- CT在新辅助化疗后判断残留病灶的阴性预测值在患者分析和病灶分析中均低,尤其对非可测量病灶及膈下间隙、肠浆膜和肠系膜。
研究设计与样本
- 回顾性观察队列研究,纳入58例接受新辅助化疗后行间歇性减瘤术的原发性III/IV期卵巢癌连续患者,将间歇性减瘤术前的CT表现与组织学/手术所见进行对照。
关键影像表现/征象
- CT在膈下间隙、肠浆膜和肠系膜检出腹膜癌病的诊断性能低(p < 0.001)。
- 假阴性结果与病灶大小相关(p < 0.001)。
诊断标准与关键数值
- 患者分析(n = 58):敏感度92.16%、特异度57.14%、阳性预测值94.00%、阴性预测值50.00%、准确率87.93%。
- 病灶分析:敏感度63.01%、特异度73.47%、阳性预测值82.51%、阴性预测值50.00%、准确率66.51%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To evaluate the diagnostic performance of contrast-enhanced computed tomography (CT) in predicting residual disease following neo-adjuvant chemotherapy (NACT) in stage III/IV ovarian cancer.
MATERIALS AND METHODS: This was a retrospective observational cohort study including consecutive patients with primary stage III/IV ovarian cancer who received NACT before interval debulking surgery. CT findings before interval debulking surgerywere correlated with histological/surgical findings. Diagnostic characteristics were calculated on patient-based and lesion-based analyses. False negative results on peritoneal carcinomatosis detection were correlated with lesion size and site.
RESULTS: On patient-based analysis, CT (n = 58) had a sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 92.16%, 57.14%, 94.00%, 50.00%, and 87.93%. On lesion-based analysis, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 63.01%, 73.47%, 82.51%, 50.00%, and 66.51%. False negative results were associated with lesion size (p < 0.001). The diagnostic performance of CT on the detection of peritoneal carcinomatosis was low at the subdiaphragmatic spaces, bowel serosa and mesentery (p < 0.001).
CONCLUSION: CT had low negative predictive value in determining residual disease following NACT on both patient-based and lesion-based analyses, especially for non-measurable lesions and at the subdiaphragmatic spaces, bowel serosa and mesentery.
引用
- An H, Chiu KWH, Tse KY, et al. The Value of Contrast-Enhanced CT in the Detection of Residual Disease After Neo-Adjuvant Chemotherapy in Ovarian Cancer. Acad Radiol. 2019. PMID: 31629627. doi:10.1016/j.acra.2019.09.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。